Temporal and Spatial Dynamics of Motor Dysfunction in Preclinical Parkinson's Disease and Aging

Navya Nair1, Grace Hey2, Alexander Becsey1

  • 1Lillian S. Wells Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, FL 32611, USA.

Journal of Psychiatry and Brain Science
|September 11, 2025
PubMed

Insights

The M83+/- mouse model shows Parkinson's Disease (PD) gait changes, including reduced limb swing and increased stride frequency after alpha-synuclein fibril injection. This model is useful for preclinical PD gait research.

Area of Science:

  • Neuroscience
  • Biomedical Engineering
  • Animal Models

Background:

  • Parkinson's Disease (PD) research often uses murine models.
  • The M83+/- mouse model of PD has been understudied for gait analysis.
  • Alpha-synuclein (α-syn) preformed fibrils (PFF) are used to induce PD-like pathology.

Purpose of the Study:

  • To assess gait abnormalities in the M83+/- mouse model of PD.
  • To investigate the effects of α-syn PFF on gait parameters in M83+/- mice.
  • To evaluate the M83+/- model's utility for preclinical PD gait studies.

Main Methods:

  • Gait metrics including swing, stride length/frequency, and ataxia were collected.
  • The DigiGait™ system was used for assessment.
  • M83+/- mice were injected with α-syn PFF or used as aged controls.

Main Results:

  • PFF-treated mice showed significantly decreased limb swing and increased stride frequency.
  • Hindlimb swing was greater in young M83+/-+PFF mice compared to aged M83+/- mice.
  • Ataxia significantly increased in PFF-treated mice across forelimbs, hindlimbs, and all limbs.

Conclusions:

  • M83+/- mice exhibit significant gait abnormalities consistent with PD.
  • The M83+/- murine model is a valuable tool for preclinical gait analysis in PD research.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
190